EUVIMEDEUVIMED entdecken
Crossref

RPL22 suppresses tumor growth in undifferentiated/dedifferentiated endometrial carcinoma through IFIT3 downregulation

Angel Chao, Chiao-Yun Lin, Wei-Jiun Tang, Chen-Yang Huang, Ren-Chin Wu, An-Shine Chao, Chyong-Huey Lai

Journal of Molecular Medicine · 2026-12 · 104 (1)

DOI: 10.1007/s00109-026-02732-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Medicine, online erschienen am 29.10.2026. Verfasst von Angel Chao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, 5 Fuxing St., Guishan,…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Ribosomal Proteins, RNA-Binding Proteins. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Ministry of Science and Technology, Chang Gung Memorial Hospital, Linkou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RPL22 mutations were identified in 42% of UDEC samples, predominantly in mismatch repair–deficient tumors. RPL22 enhanced the sensitivity of UDEC cells to multiple therapeutic agents, including cisplatin, lenvatinib, and pembrolizumab. RNA sequencing revealed that RPL22 overexpression in UDEC cells downregulated IFIT3 through the JAK/STAT signaling pathway In vivo xenograft studies demonstrated the tumor-suppressive effects of RPL22 , while IFIT3 counteracted these anti-tumor activities. RPL22 serves as a key regulator of drug sensitivity and immune responses in UDEC through modulation of the JAK/STAT–IFIT3 axis. Undifferentiated/dedifferentiated endometrial carcinoma (UDEC) represents a rare but aggressive subtype of endometrial cancer characterized by chemoresistance. Notably, a considerable proportion of patients with UDEC who exhibit mismatch repair deficiency respond favorably to immunotherapy. Here, we identified mutations in the ribosomal protein L22 ( RPL22 ) gene in 42% (11/26) of UDEC samples – which occurred predominantly in mismatch repair-deficient tumors. Functionally, we demonstrated that RPL22 increased the sensitivity of UDEC cells to cisplatin and lenvatinib, while promoting T-cell-mediated cytotoxicity in the presence of combined lenvatinib and pembrolizumab. RNA sequencing revealed that RPL22 overexpression in UDEC cells downregulated interferon signaling pathways, including interferon-induced protein with tetratricopeptide repeats 3 ( IFIT3 ). Further analyses supported a potential regulatory relationship between RPL22 , IFIT3 , and JAK/STAT1 signaling. In xenograft experiments, RPL22 overexpression reduced tumor growth, and concurrent IFIT3 overexpression attenuated this suppressive effect at the final time point. Collectively, these findings identify RPL22 as a potential regulator of drug sensitivity and immune responses in UDEC. We propose that the RPL22 - IFIT3 -JAK/STAT1 axis may offer opportunities for developing personalized therapeutic strategies in UDEC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsRibosomal ProteinsRNA-Binding ProteinsFemaleHumansAnimalsGene Expression Regulation, NeoplasticCell Line, TumorMiceDown-RegulationSignal TransductionCell ProliferationXenograft Model Antitumor AssaysIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

Interferon-induced protein with tetratricopeptide repeats 3JAK/STAT pathwayRibosomal protein L22Tumor suppressorUndifferentiated/dedifferentiated endometrial carcinoma

Substanzen

Ribosomal ProteinsRNA-Binding ProteinsIFIT3 protein, humanRPL22 protein, humanIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, 5 Fuxing St., Guishan, Taoyuan, 333, Taiwan. angel945@adm.cgmh.org.tw.
  • Department of Medical Research, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
  • Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan.
  • Department of Medical Oncology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Department of Anatomical Pathology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, 5 Fuxing St., Guishan, Taoyuan, 333, Taiwan.

Förderung

  • Ministry of Science and Technology
  • Chang Gung Memorial Hospital, Linkou

Zitieren

APA

Chao, A., Lin, C. Y., Tang, W. J., Huang, C. Y., Wu, R. C., Chao, A. S., & Lai, C. H. (2026). RPL22 suppresses tumor growth in undifferentiated/dedifferentiated endometrial carcinoma through IFIT3 downregulation. Journal of Molecular Medicine, 104(1). https://doi.org/10.1007/s00109-026-02732-3

Vancouver

Chao A, Lin CY, Tang WJ, Huang CY, Wu RC, Chao AS, et al. RPL22 suppresses tumor growth in undifferentiated/dedifferentiated endometrial carcinoma through IFIT3 downregulation. Journal of Molecular Medicine. 2026;104(1). doi:10.1007/s00109-026-02732-3

BibTeX
@article{Chao2026,
  author = {Chao, Angel and Lin, Chiao-Yun and Tang, Wei-Jiun and Huang, Chen-Yang and Wu, Ren-Chin and Chao, An-Shine and Lai, Chyong-Huey},
  title = {RPL22 suppresses tumor growth in undifferentiated/dedifferentiated endometrial carcinoma through IFIT3 downregulation},
  journal = {Journal of Molecular Medicine},
  year = {2026},
  volume = {104},
  number = {1},
  doi = {10.1007/s00109-026-02732-3}
}
Kostenlos starten →